

## REFERENCES

1. Howell DS. Pathogenesis of osteoarthritis. *Am J Med* 1986; 80(4B): 24-8.
2. Setnikar I. Antireactive properties of chondroprotective drugs. *Int J Tissue React* 1992; 14(5): 253-61.
3. Peyron J. Inflammation in osteoarthritis (OA): Review of its role in the clinical practice, disease progress, subsets and pathology. *Semin Arthritis Rheum* 1981; 11(suppl 1): 115-9.
4. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, Moskowitz RW, Schnitzer TJ. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. *Arthritis Rheum* 1995; 38(11): 1541-6.
5. Bullough P. Synovial and osseous inflammation in osteoarthritis. *Semin Arthritis Rheum* 1981; 11(suppl 1): 146.
6. Altman RD, Hochberg MC. Degenerative joint disease. *Clin Rheum Dis* 1983; 9(3) : 681-9.
7. Miller MR., Kasahara M. Observations of the innervation of human long bone. *Anat Rec* 1963; 145: 13-7.
8. Lemperg RK, Arnoldi CC. The significance of intraosseous pressure in normal and diseased states with special reference to the intraosseous engorgement-pain syndrome. *Clin Orthop* 1978; 136: 143-56.
9. Bollet AJ. Analgesic and anti-inflammatory drugs in the therapy of osteoarthritis. *Semin Arthritis Rheum* 1981; 11(suppl 1): 130-2.
10. Amadio P Jr, Cummings DM. Evaluation of acetaminophen in the management of osteoarthritis of knee. *Curr Ther Res* 1983; 1: 194-200.
11. Brooks PM, Potter SR, Buchanan WW. NSAIDs and osteoarthritis—help or hindrance? *J Rheumatol* 1982; 9(1): 3-5.
12. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. *Ann Intern Med* 1991; 114(4): 257-63.

13. Soll AH, Weinstein WM, Kurata J, McCarthy D. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. *Ann Intern Med* 1991; 114(4): 307-19.
14. Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. *N Engl J Med* 1991; 325(2): 87-91.
15. Bresnihan B, Hughes G, Essigman WK. Diflunisal in the treatment of osteoarthrosis: a double-blind study comparing diflunisal with ibuprofen. *Curr Med Res Opin* 1978; 5(7): 556-61.
16. Moxley TE, Royer GL, Hearron MS, Donovan JF, Levi L. Ibuprofen versus buffered phenylbutazone in the treatment of osteoarthritis: double-blind trial. *J Am Geriatr Soc* 1975; 23(8): 343-9.
17. de Blecourt JJ. A comparative study of ibuprofen ("Brufen") and indomethacin in uncomplicated arthrosis. *Curr Med Res Opin* 1975; 3: 477-80.
18. Cimmino MA, Cutolo M, Samanta E, Accardo S. Short-term treatment of osteoarthritis: a comparison of sodium meclofenamate and ibuprofen. *J Int Med Res* 1982; 10(1): 46-52.
19. Stamp J, Rhind V, Haslock I. A comparison of nefopam and flurbiprofen in the treatment of osteoarthrosis. *Br J Clin Pract* 1989; 43(1): 24-6.
20. Parr G, Darekar B, Fletcher A, Bulpitt CJ. Joint pain and quality of life; results of a randomised trial. *Br J Clin Pharmacol* 1989; 27(2): 235-42.
21. Coles LS, Fries JF, Kraines RG, Roth SH. From experiment to experience: side effects of nonsteroidal anti-inflammatory drugs. *Am J Med* 1983; 74(5): 820-8.
22. Lanza FL. Endoscopic studies of gastric and duodenal injury after the use of ibuprofen, aspirin, and other nonsteroidal anti-inflammatory agents. *Am J Med* 1984; 77(1A): 19-24.
23. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. *N Engl J Med* 1984; 310(9): 563-72.
24. He LF. Involvement of endogenous opioid peptides in acupuncture analgesia. *Pain* 1987; 31(1): 99-121.
25. Gordon JS. Alternative medicine and the family physician. *Am Fam Physician* 1996; 54(7): 2205-12, 2218-20.

26. Verhoef MJ, Sutherland LR. General practitioners' assessment of and interest in alternative medicine in Canada. *Soc Sci Med* 1995; 41(4): 511-5.
27. Cheng XN. *Chinese Acupuncture and Moxibustion*. Beijing: Foreign Languages Press. 1987.
28. Perrot S, Menkes CJ. Nonpharmacological approaches to pain in osteoarthritis. Available options. *Drugs* 1996; 52 (suppl 3): 21-6.
29. Senior K. Acupuncture: can it take the pain away? *Mol Med Today* 1996; 2(4): 150-3.
30. Sandler DP, Smith JC, Weinberg CR, Buckalew VM Jr, Dennis VW, Blythe WB, Burgess WP. Analgesics use and chronic renal disease. *N Engl J Med* 1989; 320: 1238-43.
31. Siraux P. Diclofenac (Voltaren) for the treatment of osteo-arthrosis: a double-blind comparison with naproxen. *J Int Med Res* 1977; 5(3): 169-74.
32. Shaikh KA, Ali M, Sharafatullah T. Comparative study of diclofenac sodium and flurbiprofen in osteoarthritis. *JPMA* 1996; 46(12): 270-2.
33. Ward JR. Efficacy of diclofenac in osteoarthritis. Experience in the United States. *Am J Med* 1986; 80(4B): 53-7.
34. Bellamy N, Bensen WG, Beaulieu A, Siminovitch KA, Kraag GR, Lussier A, Ahmad S, Khanna VN, Davis P, Bell MJ. A multicenter study of nabumetone and diclofenac SR in patients with osteoarthritis. *J Rheumatol* 1995; 22(5): 915-20.
35. Grisanti AM, Vaz AA, Samara AM. Comparison of etodolac and diclofenac in osteoarthritis of the knee. *Clin Ther* 1992; 14(6): 791-800.
36. Kidd B, Frenzel W. A multicenter, randomized, double blind study comparing lornoxicam with diclofenac in osteoarthritis. *J Rheumatol* 1996; 23(9): 1605-11.
37. Bellamy N, Buchanan WW, Chalmers A, Ford PM, Kean WF, Kraag GR, Gercz Simon E, Campbell J. A multicenter study of tenoxicam and diclofenac in patients with osteoarthritis of the knee. *J Rheumatol* 1993; 20(6): 999-1004.
38. Bellamy N, Bensen WG, Ford PM, Huang SH, Lang JY. Double-blind randomized controlled trial of flurbiprofen-SR (ANSAID-SR) and diclofenac sodium-SR (Voltaren-SR) in the treatment of osteoarthritis. *Clin Invest Med* 1992; 15(5): 427-33.

39. Melo Gomes JA, Roth SH, Zeeh J, Bruyn GA, Woods EM, Geis GS. Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. *Ann Rheum Dis* 1993; 52(12): 881-5.
40. Han JS, Terenius L. Neurochemical basis of acupuncture analgesia. *Annu Rev Pharmacol Toxicol* 1982; 22: 193-220.
41. Cashman JN. The mechanisms of action of NSAIDs in analgesia. *Drugs* 1996; 52 (suppl 5): 13-23.
42. Bjorkman R. Central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol. Experimental studies in the rat. *Acta Anaesthesiol Scand* 1995; 103(suppl) : 1-44.
43. Richardson PH, Vincent CA. Acupuncture for the treatment of pain: a review of evaluative research. *Pain* 1986; 24(1): 15-40.
44. Christensen BV, Iuhl IU, Vilbek H, Bulow HH, Dreijer NC, Rasmussen HF. Acupuncture treatment of severe knee osteoarthritis. A long-term study. *Acta Anaesthesiol Scand* 1992; 36(6): 519-25.
45. Takeda W, Wessel J. Acupuncture for the treatment of pain of osteoarthritic knees. *Arthritis Care Res* 1994; 7(3): 118-22.
46. Gaw AC, Chang LW, Shaw LC. Efficacy of acupuncture on osteoarthritic pain. A controlled, double-blind study. *N Engl J Med* 1975; 293(8): 375-8.
47. Stux G, Pomeranz B. *Basics of Acupuncture*. New York: Springer-Verlag Berlin Heidelberg. 1998.
48. He L. Effect of iontophoretic etorphine and electroacupuncture on nociceptive response from nucleus lateralis anterioris of thalamus in rabbits. *Acupunct Electrother Res* 1981; 6(2-3): 151-7.
49. Cheng RS, Pomeranz B. A combined treatment with D-amino acids and electroacupuncture produces a greater analgesia than either treatment alone; naloxone reverses these effects. *Pain* 1980; 8(2): 231-6.
50. Way WL, Way EL, Fields HL: "Opioid analgesics & antagonists" in *Basic & Clinical Pharmacology*, 6th ed. Prentice-Hall International Inc: London, pp. 460-72, 1995
51. Domer F. Characterization of the analgesic activity of ketorolac in mice. *Eur J Pharmacol* 1990; 177(3): 127-35.

52. Vescovi P, Passeri M, Gerra G, Grossi E. Naloxone inhibits the early phase of diclofenac analgesia in man. *Pain Clinic* 1987; 19: 151-5.
53. Martini A, Bondiolotti GP, Sacerdote P, Pierro L, Picotti GB, Panerai AE, Restelli L, Zancaner F, Monza G. Diclofenac increases beta-endorphin plasma concentrations. *J Int Med Res* 1984; 12(2): 92-5.
54. Gerra G, Vescovi PP, Pezzarossa A. Successful treatment of opiate withdrawal using lysine acetylsalicylate. *Current Ther Res* 1983; 33: 733-9.
55. Gerra G, Ceresini G, Rastelli G, Butturini L, Vescovi PP. Effect of diclofenac on the opiate withdrawal syndrome. *G Clin Med* 1985; 66(11-12): 459-65.
56. Urba SG. Nonpharmacologic pain management in terminal care. *Clin Geriatr Med* 1996; 12(2): 301-11.
57. Heinegard D, Hascall VC. Aggregation of cartilage proteoglycans. III. Characteristics of the proteins isolated from trypsin digests of aggregates. *J Biol Chem* 1974; 249(13): 4250-6.
58. Thonar EJ-MA, Lenz ME, Klintworth GK, Caterson B, Pachman LM, Glickman P, Katz R, Huff J, Kuettner KE. Quantification of keratan sulfate in blood as a marker of cartilage catabolism. *Arthritis Rheum* 1985; 28(12): 1367-76.
59. Sharif M, George E, Dieppe PA. Correlation between synovial fluid markers of cartilage and bone turnover and scintigraphic scan abnormalities in osteoarthritis of the knee. *Arthritis Rheum* 1995; 38(1): 78-81.
60. Fraser JR, Appelgren LE, Laurent TC. Tissue uptake of circulating hyaluronic acid. A whole body autoradiographic study. *Cell Tissue Res* 1983; 233: 285-93.
61. Ratcliffe A, Shurety W, Caterson B. The quantitation of a native chondroitin sulphate epitope in synovial fluid lavages and articular cartilage from canine experimental osteoarthritis and disuse atrophy. *Arthritis Rheum* 1993; 36(4): 543-51.
62. Kempson GE, Tuke MA, Dingle JT, Barrett AJ, Horsfield PH. The effects of proteolytic enzymes on the mechanical properties of adult human articular cartilage. *Biochim Biophys Acta* 1976; 428(3): 741-60.
63. Burkhardt D, Ghosh P. Laboratory evaluation of antiarthritic drugs as potential chondroprotective agents. *Semin Arthritis Rheum* 1987; 17(suppl 1): 3-34.
64. Ratcliffe A, Seibel MJ. Biochemical markers of osteoarthritis. *Curr Opin Rheumatol* 1990; 2: 770-6.

65. Thonar EJ-MA, Sweet M, Immelman A. Hyaluronate in articular cartilage: Age-related changes. *Calcif Tissue Res* 1978; 26: 19-21.
66. Ghosh P, Sutherland JM, Taylor TK, Bellenger CR, Pettit GD. The effect of bilateral medial meniscectomy on articular cartilage of the hip joint. *J Rheumatol* 1984; 11 (2): 197-201.
67. Sharif M, George E, Shepstone L, Knudson W, Thonar EJ-MA, Cushnaghan J, Dieppe P. Serum hyaluronic acid level as a predictor of disease progression in osteoarthritis of the knee. *Arthritis Rheum* 1995; 38: 760-7.
68. Cooper EH, Rathbone BJ. Clinical significance of the immunometric measurements of hyaluronic acid. *Ann Clin Biochem* 1990; 27: 444-51.
69. Hardingham T. Changes in chondroitin sulphate structure induced by joint disease. *Acta Orthop Scand* 1995; 66(266): 107-10.
70. Kongtawelert P, Pothacharoen P, Teekachunhatean S, Louthrenoo W, Yingsung W, Ong-chai S, Hardingham TE. Raised chondroitin sulphate epitopes and hyaluronan in rheumatoid arthritis and osteoarthritic human serum (submitted for publication in *Rheumatol*).
71. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW: Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. *J Rheumatol* 1988; 15: 1833-40.
72. Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severity for osteoarthritis of the hip and knee validation-value in comparison with other assessment tests. *Scand J Rheumatology* 1987; 65(suppl): 85-9.
73. Surangkul D. "The development of methods for quantitation of serum total sialic acid and hyaluronan". M.S. Thesis, Graduate School, Chiang Mai University, Chiang Mai, Thailand, 1998.
74. Hazell PK, Dent C, Fairclough JA, Bayliss MT, Hardingham T. Changes in glycosaminoglycan epitopes levels in knee joint fluid following injury. *Arthritis Rheumatism* 1995; 38(7): 953-959.
75. Caterson B, Mahmoodian F, Sorrell JM, Hardingham T, Bayliss MT, Carney SL, Ratcliffe A, Muir H. Modulation of native chondroitin sulphate structure in tissue development and in disease. *J Cell Sci* 1990; 97: 411-417.

76. Tiengburanathum N. "The production and characterization of monoclonal antibody against chondroitin sulphate C". M.S. Thesis, Graduate School, Chiang Mai University, Thailand, 1996.
77. Kellgren JH, Lawrence JS. Radiological assessment of osteoarthritis. *Ann Rheum Dis* 1957; 16: 494-502.
78. Birch S, Hammerschlag R. Acupuncture efficacy: A compendium of controlled trials. New York: National Academy of Acupuncture and Oriental Medicine. 1996.
79. Berman BM, Singh BB, Lao L, Langenberg P, Li H, Hadhazy V, Baretta J, Hochberg M. A randomized trial of acupuncture as an adjunctive therapy in osteoarthritis of the knee. *Rheumatol* 1999; 38: 346-54.
80. Lister BJ, Poland M, Delapp RE. Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. *Am J Med* 1993; 95: 2-9.
81. Bellamy N. Outcome measurement in osteoarthritis clinical trials. *J Rheumatol* 1995; 22(suppl 43): 49-51.
82. Manicourt DH, Egeren AD, Haazen L, Deuxchaisnes CN. Effects of tenoxicam and aspirin on the metabolism of proteoglycans and hyaluronan in normal and osteoarthritic human articular cartilage. *Br J Pharmacol* 1994; 113: 1113-20.
83. Carroll GJ, Bell MC, Laing BA, McCappin S, Blumer C, Leslie A. Reduction of the concentration and total amount of keratan sulphate in synovial fluid from patients with osteoarthritis during treatment with piroxicam. *Ann Rheum Dis* 1992; 51: 850-4.
84. Lohmander LS and Felson DT: "Defining and validating the clinical role of molecular markers in osteoarthritis." in *Osteoarthritis*, 1st ed. Oxford University Press., New York, pp. 519-29, 1998.
85. Rubin BR, Talent JM, Kongtawelert P, Pertusi RM, Forman MD, Gracy RW. Oral polymeric N-acetyl-D-glucosamine and osteoarthritis (submitted for publication in *JAOA*).